Metabolic effects of antipsychotics in children.

Trial Profile

Metabolic effects of antipsychotics in children.

Phase of Trial: Phase IV

Latest Information Update: 10 Dec 2015

At a glance

  • Drugs Aripiprazole (Primary) ; Olanzapine (Primary) ; Risperidone (Primary)
  • Indications Behavioural disorders; Psychotic disorders
  • Focus Adverse reactions; Pharmacodynamics
  • Acronyms MEAC
  • Most Recent Events

    • 02 Aug 2011 Additional lead trial investigator (Ginger Nicol) identified as reported by
    • 02 Aug 2011 Status changed from active, no longer recruiting to completed as reported by
    • 28 Jun 2011 Results presented at the 71st Annual Scientific Sessions of the American Diabetes Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top